Chronic myelogenous leukemia: A review

American Journal of Medicine

Volumn 100, Issue 5, 1996, Pages 555-570

  Cortes, Jorge E ^a   Talpaz, Moshe ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GAMMA INTERFERON; HOMOHARRINGTONINE; HYDROXYUREA; MELPHALAN; MERCAPTOPURINE; THIOTEPA; TIOGUANINE; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; BLAST CELL CRISIS; BLOOD TOXICITY; BONE MARROW PURGING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHROMOSOME TRANSLOCATION 9; CHRONIC FATIGUE SYNDROME; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; WHOLE BODY RADIATION;

EID: 0029895933     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00061-7     Document Type: Review

References (195)

1. Silver RT. Chronic myeloid leukemia. A perspective of the clinical and biologic issues of the chronic phase. Hematol Oncol Clin North Am. 1990;4:319-335.
2. Champlin RE, Golde DW. Chronic myelogenous leukemia: recent advances. Blood. 1985;65:1039-1047.
3. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
4. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125-130.
5. Pialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA. 1967;58:1468-1471.
6. 1-positive chronic myelogenous leukemia. Blood. 1978;51:1039-1044.
7. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85-109.
8. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
9. Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature. 1982;300:765-767.
10. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature. 1983;306:277-280.
11. Talpaz M, Kantarjian HM, McCredie KB, et al. Clinical investigation of human alpha Interferon in chronic myelogenous leukemia. Blood. 1987;69:1280-1288.
12. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival following achievement of cytogenetic response with alpha Interferon therapy in chronic myelogenous leukemia. Ann Intern Med. 1995;122:254-261.
13. Gift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood. 1993;82:1954-1956.
14. Morrison VA. Chronic leukemias. CA Cancer J Clin. 1994;44:353-377.
15. Brincker H. Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia. Scand J Haematol. 1982;29:241-249.
16. Call T G, Noel P, Habermann TM, Beard CM, O'Fallon M, Kurland LT. Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1994;69:315-322.
17. Hughes TP, Goldman JM: Chronic myeloid leukemia. In: Hoffman R, Benz EJ, Jr, Shattil SJ, et al, eds. Hematology. Basic Principles and Practice. New York: Churchill Livingstone, 1991:854-869.
18. Moloney WC. Natural history of chronic granulocytic leukaemia. Clin Haematol 1977;6:41-60.
19. Baranovsky A, Myers MH. Cancer incidence and survival in patients 65 years of age and older. CA Cancer J Clin. 1986;36:26-41.
20. Lawler SD. The cytogenetics of chronic granulocytic leukaemia. Clin Haematol. 1977;6:55-75.
21. Bortin MM, D'Amaro J, Bach FH, Rimm AA, van Rood JJ. HLA associations with leukemia. Blood. 1987;70:227-232.
22. Heyssel R, Brill AB, Woodbury LA, Nishimura ET, Ghose T, Hoshino T, Yamasaki M. Leukemia in Hiroshima atomic bomb survivors. Blood. 1960;15:313-331.
23. Moloney WC. Radiogenic leukemia revisited. Blood. 1987;70:905-908.
24. Brown WMC, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J. 1965;2:1327-1332.
25. Boice JD, Day NE, Andersen A, Brinton LA, et al. Second cancer following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst. 1985;74:955-975.
26. Spiers ASD. The clinical features of chronic granulocytic leukaemia. Clin Hematol 1977;6:77-95.
27. Lichtman MA, Rowe JM. Hyperleukocytic leukemias: Theological, clinical, and therapeutic considerations, Blood. 1982;60:279-283.
28. Juan D, Hsu S-D, Hunter J. Case report of vasopressin-responsive diabetes insipidus associated with chronic myelogenous leukemia. Cancer. 1985;56:1468-1469.
29. Kantarjian HM, Dixon D, Heating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
30. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88:1-8.
31. Canellos GP. Chronic granulocytic leukemia. Med Clin North Am. 1976;60:1001-1018.
32. Inbal A, Akstein E, Barak I, Meytes D, Many A. Cyclic leukocytosis and long survival in chronic myeloid leukemia. Acta Haematol. 1983;69:353-357.
33. Dowding C, Th'ng KH, Goldman JM, Galton DA. Increased T-lymphocyte numbers in chronic granulocytic leukemia before treatment. Exp Hematol. 1984;12:811-815.
34. Cramer E, Auclair C, Hakim J, et al. Metabolic activity of phagocytosing granulocytes in chronic granulocytic leukemia: ultrastructural observation of a degranulation defect. Blood. 1977;50:93-106.
35. Fujimiya Y, Chang W-C, Bakke A, Horwitz D, Pattengale PK. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. Cancer Immunol Immunother. 1987;24:213-220.
36. Knox WF, Bhavnani M, Davson J, Geary CG. Histological classification of chronic granulocytic leukaemia. Clin Lab Haematol. 1984;6:171-175.
37. Dosik H, Rosner F, Sawitsky A. Acquired lipidosis: Gaucher-like cells and "blue cells" in chronic granulocytic leukemia. Semin Hematol. 1972;9:309-316.
38. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59:1739-1743.
39. Rosner F, Schreiber ZR, Parise F. Leukocyte alkaline phosphatase. Arch Intern Med. 1972;130:892-894.
40. Rustin GJS, Goldman JM, McCarthy D, Mees S, Peters TJ. An extrinsic factor controls neutrophil alkaline phosphatase synthesis in chronic granulocytic leukaemia. Br J Haematol. 1980;45:381-387.
41. Yuo A, Kitagawa S, Okabe T, Urabe A, Komatsu Y, Itoh S, Takaku F. Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic my-elogenous leukemia. Blood, 1987;70:404-411.
42. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445-454.
43. Jacknow G, Frizzera G, Gajl-Peczalska K, et al. Extramedullary presentation of the blast crisis of chronic myelogenous leukemia. Br J Haematol. 1985;61:225-236.
44. Terjanian T, Kantarjian H, Keating M, Talpaz M, McCredie K, Freireich EJ. Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer. 1987;59:297-300.
45. Derderian PM, Kantarjian HM, Talpaz M, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med. 1993;94:69-74.
46. Majlis A, Kantarjian H, Smith T, et al. What is the significance of cytogenetic clonal evolution in patients with Philadelphia chromosome-positive chronic myelogenous leukemia? Blood. 1994;84(Suppl 1):150a(abstr).
47. Tura S, Baccarani M, Corbelli G, the Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Staging of chronic myeloid leukaemia. Br J Haematol. 1981;47:105-119.
48. Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood. 1982;60:1298-1304.
49. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
50. Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985;66:1326-1335.
51. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
52. Cervantes F, Robertson JE, Rozman C, et al. Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Br J Haematol. 1994;87:293-300.
53. Futaki M, Inokuchi K, Matsuoka H, Miyake K, Dan K, Nomura T. Relationship of the type of BCR-ABL hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia. Leukemia Res. 1992;16:1071-1075.
54. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood. 1991;78:1155-1161.
55. Verschraegen C, Talpaz M, Hirsch-Ginsberg C, et al. Prognostic relevance of 3′ versus 5′ breakpoints within the breakpoint cluster region of chromosome 22 in Philadelphia positive chronic myelogenous leukemia. Blood. 1995;85:2705-2710.
56. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990-998.
57. Gale RP, Canaani E. An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 1984;81:5648-5652.
58. Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian H. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med. 1994;97:60-65.
59. 1-positive acute lymphocytic leukaemia. Nature. 1987;325:635-637.
60. Muller AJ, Young JC, Pendergast A-M, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol. 1991;11:1785-1792.
61. McWhirter JR, Wang JYJ. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cel Biol. 1991;11:1553-1565.
62. bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
63. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344:251-253.
64. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a Non-phosphotyrosine-dependent manner. Cell. 1991;66:161-171.
65. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185.
66. Lowenstein EJ, Daly RJ, Batzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 1992;70:431-442.
67. Smith MR, DeGudicibus SJ, Stacey DW. Requirement for c-ras proteins during viral oncogene transformation. Nature. 1986;320:540-543.
68. McWhirter JR, Wang JYJ. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J. 1993;12:1533-1546.
69. + leukemia. Blood. 1994;84:1731-1736.
70. Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc. Science. 1994;264:424-426.
71. Evans CA, Owen-Lynch PJ, Whetton AD, Dive C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res. 1993;53:1735-1738.
72. Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86:1148-1158.
73. Melo JV, Gordon DE, Cross NCP, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood. 1993;81:158-165.
74. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest. 1991;87:2042-2047.
75. Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res. 1992;52:6588-6593.
76. Neubauer A, He M, Schmidt CA, Huhn D, Liu ET. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis of polymerase chain reaction based techniques. Leukemia. 1993;7:593-600.
77. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc NatlAcad Sci USA. 1991;88:6293-6297.
78. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukemia. Nature. 1987;328:342-344.
79. Upadhyaya G, Guba SC, Sih SA, et al. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest. 1991;88:2131-2136.
80. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1integrin receptor function. J Clin Invest. 1994;94:384-391.
81. Estrov Z, Kurzrock R, Wetzler M, et al. Suppression of chronic myelogenous leukemia colony growth by IL-1 receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991;78:1476-1484.
82. Wetzler M, Kurzrock R, Estrov Z, et al. Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994;84:3142-3147.
83. Rushing D, Goldman A, Gibbs G, Howe R, Kennedy BJ. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Am J Clin Oncol. 1982;5:307-313.
84. Kolitz JE, Kempin SJ, Schluger A, et al. A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia. Semin Oncol. 1992;19(Suppl 9):27-33.
85. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood. 1993;83:398-407.
86. Robertson MJ, Tantravahi R, Griffin JD, Canellos GP, Cannistra SA. Hematologie remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993;43:95-102.
87. Shepherd PCA, Fooks J, Gray R, Allan NC. Thioguanine used in maintenance therapy of chronic myeloid leukemia causes non-cirrhotic portal hypertension. Br J Haematol. 1991;79:185-192.
88. Renner D, Queisser U, Martinez C, Queisser W. Treatment of excessive thrombocytopenia in chronic myeloid leukemia by thombocytopheresis and intravenous Thio-TEPA. Onkologie. 1987;10:324-326.
89. O'Brien S, Kantarjian H, Feldman E, et al. Homoharringtonine produces high hematologic and cytogenetic response rates in Philadelphia-chromosome positive chronic myelogenous leukemia. Blood. 1992;80(Suppl 1):358(abstr).
90. O'Brien S, Kantarjian H, Beran M, et al. Homoharringtonine produces high response rates in Philadelphia chromosome positive chronic myelogenous leukemia. Blood. 1991;78(Suppl 1):170(abstr).
91. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alfa Interferon in chronic myelogenous leukemia. Blood. 1987;69:1280-1288.
92. A in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065-1069.
93. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114:532-538.
94. Ozer H, George S, Pettenati M, et al. Subcutaneous a-interferon in untreated chronic phase Philadelphia chromosome positive chronic myelogenous leukemia: no evidence for significant improvement in response duration or survival (CALGB 8583). Blood 1992;80(Suppl 1):358(abstr).
95. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med. 1994;121:736-744.
96. Allan NC, Shepherd PCA, Richards SM. Interferon-α prolongs survival for patients with CML in chronic phase: preliminary results of the UK MRC randomized multicenter trial. Blood. 1994;84(Suppl 1):382(abstr).
97. Kloke O, Niederle N, Qiu JY, et al. Impact of Interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukemia. Br J Haematol. 1993;83:399-403.
98. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of Interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84:4064-4077.
99. Niederle N, Kloke O, Osieka R, Wandl U, Opalka B, Schmidt CG. Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol. 1987;14:29-35.
100. Kluin-Nelemans JC, Lowagie A, Delannoy A, et al. CML treated by Interferon alfa-2b vs hydroxyurea alone: preliminary report of a large multicenter randomized trial. Blood 1992;80(Suppl 1):358(abstr).
101. Alimena G, Morra E, Lazzarino M, et al. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood. 1988;72:642-647.
102. Freund M, von Wussow P, Diedrich H, et al. Recombinant human Interferon alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol. 1989;72:350-356.
103. Anger B, Porzolt F, Leichte R, Heinze B, Bartram C, Heimpel H. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut. 1989;58:275-278.
104. Cortes J, Kantarjian H, O'Brien S, Robertson L, Pierce S, Talpaz M. Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Proc ASCO. 1995;14:339(abstr).
105. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906-916.
106. Kurzrock R, Talpaz M, Kantarjian H, et al. Therapy of chronic myelogenous leukemia with recombinant interferon-a. Blood 1987;70:943-947.
107. Talpaz M, Kurzrock R, Kantarjian H, et al. A phase II study alternating alpha-2a-Interferon and gamma-Interfeon therapy in patients with chronic myelogenous leukemia. Cancer. 1991;68:2125-2130.
108. Wandl UB, Kloke O, Nagel-Hiemke M, et al. Combination therapy with Interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukemia. Br J Haematol. 1992;81:516-519.
109. Kloke O, Wandl U, Opalka B, et al. A prospective randomized comparison of single-agent interferon-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. Eur J Haematol. 1992;48:93-98.
110. Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with Interferon-α and low-dose cytarabine. J Clin Oncol. 1992;10:772-778.
111. Arthur CK, Ma DDF. Combined Interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol. 1993;89(Suppl 1):15-21.
112. + chronic myelocytic leukemia: preliminary cytogenetic results. Leukemia Lympnoma. 1993;11(Suppl 1):181-183.
113. Kantarjian HM, Vellekoop L, McCredie KB, et al. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol. 1985;3:192-200.
114. Kantarjian HM, Talpaz M, Keating MJ, et al. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 1991;68:1201-1207.
115. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986;4:234-243.
116. Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer. 1992;69:410-412.
117. Sacchi S, Kantarjian H, Cohen P, Pierce S, Talpaz M. Immune-mediated and unusual complications during alpha-interferon therapy in chronic myelogenous leukemia. Blood. 1994;84(Suppl 1):150(abstr).
118. Champlin R, McGlave P. Allogeneic bone marrow transplantation for chronic myeloid leukemia. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific Publications, 1994:595-606.
119. Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 1993;12:509-516.
120. Biggs JC, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992;80:1352-1357.
121. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood. 1991;77:1660-1665.
122. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036-2043.
123. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 1988;108:806-814.
124. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Lancet. 1984;i:665-668.
125. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104:155-163.
126. Wagner JE, Zahurak M, Piantadosi S, et al. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. J Clin Oncol. 1992;10:779-789.
127. Giralt SA, Kantarjian HM, Talpaz M, et al. Effect of prior interferon therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993;11:1055-1061.
128. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-α in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981-2990.
129. McGlave PB. Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation. Leukemia. 1992;6:115-117.
130. Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235-2238.
131. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic bone marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplant Group. Blood, 1994;83:2723-2730.
132. Snyder DS, Negrin RS, O'Donnell MR, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood. 1994;84:1672-1679.
133. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120-2130.
134. Scattenberg A, De Witte T, Preijers F, et al. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood 1990;75:1356-1363.
135. Barrett A, Jiang YZ. Immune responses to chronic myeloid leukemia. Bone Marrow Transplant. 1992;9:305-311.
136. Cullis JO, Scwarer AP, Hughes TP, et al. Second transplants for patients with chronic myeloid leukemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulfan alone for re-conditioning. Br J Haematol. 1992;80:33-39.
137. Bär BMAM, Schattenberg A, Mensink EJBM, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol. 1993;11:513-519.
138. Kolb HJ, Mittermüller J, Clemm Ch, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients, Blood. 1990;76:2462-2465.
139. Cullis JO, Jiang YZ, Scwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 1992;79:1379-1381.
140. Jiang Y-Z, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusions to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant. 1993;11:133-138.
141. Drobyski W, Keevr C, Roth M, et al. Donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1993;82:2310.
142. Higano CS, Raskind WH, Singer JW. Use of a Interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood. 1992;80:1437-1442.
143. Higano C, Raskind W, Singer J. Alpha Interferon treatment of cytogenetic-only relapse of chronic myelogenous leukemia after marrow transplantation. Proc ASCO. 1993;12:307(abstr).
144. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;30:100-106.
145. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 1993;81:543-550.
146. Garnis AS, Haake R, McGlave P, Ramsay NKC. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol. 1993;11:834-838.
147. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G, Hoffman R. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood. 1993;81:801-807.
148. Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood. 1992;79:1003-1010.
149. Carella AM, Pollicardo N, Pungolino E, et al. Mobilization of cytogenetically 'normal' blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leukemia Lympnoma. 1993;9:477-483.
150. Kantarjian H, Talpaz M, Hester J, Liang J, Deisseroth A. Collection of peripheral blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive chemotherapy. Blood. 1994;84(Suppl 1):382(abstr).
151. Kantarjian HM, Talpaz M, LeMaistre CF, et al. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer. 1991;67:2959-2965.
152. Brito-Babapulle F, Bowcock SJ, Marcus RE, et al. Autografting for patients with chronic myeloid leukemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Haematol. 1989;73:76-81.
153. Talpaz M, Kantarjian H, Liang J, et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 1995;85:3257-3263.
154. Reiffers J, Trouette R, Marit G, et al. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br J Haematol. 1991;77:339-345.
155. Khouri IF, Kantarjian HM, Talpaz M, et al. High-dose chemotherapy and unpurged autologous stem cell transplantation for chronic myelogenous leukemia: The MD Anderson experience. Blood. 1994;84(Suppl 1):537(abstr).
156. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994;83:3068-3076.
157. Dunbar CE, Stewart FM. Separating the wheat from the chaff: selection of benign hematopoietic cells in chronic myeloid leukemia. Blood. 1992;79:1107-1110.
158. Turhan AG, Humphries RK, Eaves CJ, et al. Detection of breakpoint cluster region-negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow. Blood. 1990;76:2404-2410.
159. Brandwein JM, Dube ID, Laraya P, Keating A. Maintenance of Philadelphiachromosome-positive progenitors in long-term marrow cultures from patients with advanced chronic myeloid leukemia. Leukemia. 1992;6:556-561.
160. Carlo-Stella C, Mangoni L, Piovani G, et al. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and reconbinant granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant 1991;8:265-273.
161. Rizzoli V, Mangoni L, Piovani G, et al. Mafosfamide purged autografts for chronic myelogenous leukemia. Blood. 1992;80(Suppl 1):66(abstr).
162. McGlave P, Miller J, Miller W, et al. Autologous marrow transplant therapy for CML using marrow treated ex vivo with human recombinant Interferon gamma. Blood. 1992;80(Suppl 1):537(abstr).
163. Ratajczak MZ, Hijiya N, Catani L, et al. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood. 1992;79:1956-1961.
164. Szczylik C, Skorski T, Nicolaides NC, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 1991;253:562-565.
165. Mahon FX, Belloc F, Barbot C, et al. Chronic myelogenous leukemia: in vitro study with antisense oligomers. Blood. 1992;80(Suppl l):211(abstr).
166. BCR/ABL and inhibit the proliferation of BCR/ABL-containing cell lines. Blood. 1993;81:502-509.
167. BCR/ABL protein. Proc Natl Acad Sci USA. 1992;89:1468-1472.
168. Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow inchronic myeloid leukemia: results of a pilot study. Blood. 1994;84:724-732.
169. Rowe J, Ryan D, Dipersio J, et al. Autografting in chronic myelogenous leukemia followed by inmunotherapy. Stem Cell. 1993;11(suppl 3):34-42.)
170. Bilhou-Nabera C, Viard F, Marit G, et al. Complete cytogenetic conversion in chronic myelocytic leukemia patients undergoing Interferon a therapy: follow-up with reverse polymerase chain reaction. Leukemia. 1992;6:595-598.
171. Lee M-S, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following Interferon therapy, Blood. 1992; 79:1920-1923.
172. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. J Clin Invest. 1994;94:1383-1389.
173. Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia. 1992;6:495-499.
174. Malinge M-C, Mahon FX, Delfau MH, et al. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukemia under interferon therapy. Br J Haematol. 1992;82:701-707.
175. Zhao L, Kantarjian HM, Van Oort J, Cork A, Trujillo JM, Liang JC. Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment. Leukemia. 1993;7:168-171.
176. Amiel A, Yarkoni S, Fejgin M, et al. Clinical detection of BCR-ABL fusion by in situ hybridization in chronic myelogenous leukemia. Cancer Genet Cytogenet. 1993;65:32-34.
177. Seong DC, Kantarjian HM, Ro JY, et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood. 1995;86:2343-2349.
178. Bilhou-Nabera C, Bernard Ph, Marit G, et al. Serial cytogenetic studies in allografted patients with chronic myeloid leukemia. Bone Marrow Transplant. 1992;9:263-268.
179. Hughes TP, Morgan GJ, Martial P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood. 1991;77:874-878.
180. Hughes TP, Ambrosetti A, Barbu V, et al. Clinical value of PCR in diagnosis and follow-up in leukaemia and lymphoma: report of the third workshop of the Molecular Biology/BMT Study Group. Leukemia. 1991;5:448-451.
181. Lee M, Khouri I, Champlin R, et al. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukemia following allogeneic bone marrow transplantation. Br J Haematol. 1992;82:708-714.
182. Arnold R, Janssen JWG, Heinze B, et al. Influence of graft-versus-host disease on the eradication of minimal residual leukemia detected by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation. Leukemia. 1993;7:747-751.
183. Roth MS, Antin JH, Ash R, et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia, Blood. 1992;79:276-282.
184. Guerrasio A, Martinelli G, Saglio G, et al. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: Low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants. Leukemia. 1992;6:507-512.
185. Miyamura K, Tahara T, Tanimoto M, et al. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood. 1993;81:1089-1093.
186. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82:1929-1936.
187. Kantarjian HM, Talpaz M, Kontoyiannis D, et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992;10:398-405.
188. Dutcher JP, Eudey L, Wiernik PH, et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia. 1992;6:770-775.
189. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994;84:4368-4373.
190. McGlave PB, Arthur DC, Weisdorf D, et al. Allogeneic bone marrow transplantation as treatment for accelerating chronic myelogenous leukemia. Blood. 1984;63:219-222.
191. Reiffers J, Trouette R, Marit G, et al. Autologous blood stem cell transplantation for chronic granulocytic leukemia in transformation: a report of 47 cases. Br J Haematol. 1991;77:339-345.
192. Kantarjian H, Kurzrock R, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Hematol Oncol Clin North Am. 1990;4:389-404.
193. Dobrovic A, Morley AA, Seshadri R, Januszewicz EH. Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: clinical features and course of M-bcr negative and M-bcr-positive CML. Leukemia. 1991;5:187-190.
194. Cortes J, Talpaz M, O'Brien S, Rios MB, Stass S, Kantarjian H. Philadelphia-chromosome negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region: long-term follow-up results. Cancer. 1995;75:464-470.
195. Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood. 1990;75:445-452.